β-blockers in the management of hypertension: Focus on nebivolol

David Wojciechowski, Vasilios Papademetriou

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Hypertension is a major cardiovascular risk factor but most patients remain asymptomatic for many years. Successful therapy not only needs to be effective, it also needs to be well tolerated. β-blockers are well established as effective antihypertensive agents. However, one major drawback to the currently available β-blockers, particularly the noncardioselective β-blockers, is their side-effect profile, including sexual dysfunction, fatigue, depression and metabolic abnormalities such as impaired glucose tolerance and lipid abnormalities. Nebivolol (Bystolic®), a novel, highly cardioselective, th ird-gene ration β-blocker that recently received approval by the US FDA for the treatment of hypertension in the USA, is effective in treating blood pressure and has a favorable side-effect profile. Studies conducted in Europe, where nebivolol has been available for some time for the treatment of hypertension, have shown that nebivolol achieves blood pressure reductions comparable to other β-blockers but with fewer side effects. Additionally, nebivolol has demonstrated similar efficacy in blood pressure reduction when compared with calcium channel blockers and inhibitors of the renin-angiotensin system. When combined with hydrochlorothiazicle there was an additive antihypertensive effect. Lastly, nebivolol exhibits a vasoclilatory property that is related to its effect on nitric oxide, an intrinsic vasodilator produced in the vascular endothelium. Nebivolol enhances nitric oxide bioavailablility. Studies have also demonstrated nebivolol's ability to function as an antioxidant and decrease markers of oxidative stress. These effects are believed to ultimately produce a modulation of the endothelial dysfunction typically seen in hypertension.

Original languageEnglish (US)
Pages (from-to)471-479
Number of pages9
JournalExpert Review of Cardiovascular Therapy
Volume6
Issue number4
DOIs
StatePublished - Apr 1 2008
Externally publishedYes

Fingerprint

Nebivolol
Hypertension
Blood Pressure
Antihypertensive Agents
Nitric Oxide
Glucose Intolerance
Vascular Endothelium
Calcium Channel Blockers
Renin-Angiotensin System
Vasodilator Agents

Keywords

  • β-blockers
  • Hypertension
  • Nebivolol
  • Nitric oxide

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

β-blockers in the management of hypertension : Focus on nebivolol. / Wojciechowski, David; Papademetriou, Vasilios.

In: Expert Review of Cardiovascular Therapy, Vol. 6, No. 4, 01.04.2008, p. 471-479.

Research output: Contribution to journalArticle

@article{8dc229b87b2148878b2498e6cb2514e7,
title = "β-blockers in the management of hypertension: Focus on nebivolol",
abstract = "Hypertension is a major cardiovascular risk factor but most patients remain asymptomatic for many years. Successful therapy not only needs to be effective, it also needs to be well tolerated. β-blockers are well established as effective antihypertensive agents. However, one major drawback to the currently available β-blockers, particularly the noncardioselective β-blockers, is their side-effect profile, including sexual dysfunction, fatigue, depression and metabolic abnormalities such as impaired glucose tolerance and lipid abnormalities. Nebivolol (Bystolic{\circledR}), a novel, highly cardioselective, th ird-gene ration β-blocker that recently received approval by the US FDA for the treatment of hypertension in the USA, is effective in treating blood pressure and has a favorable side-effect profile. Studies conducted in Europe, where nebivolol has been available for some time for the treatment of hypertension, have shown that nebivolol achieves blood pressure reductions comparable to other β-blockers but with fewer side effects. Additionally, nebivolol has demonstrated similar efficacy in blood pressure reduction when compared with calcium channel blockers and inhibitors of the renin-angiotensin system. When combined with hydrochlorothiazicle there was an additive antihypertensive effect. Lastly, nebivolol exhibits a vasoclilatory property that is related to its effect on nitric oxide, an intrinsic vasodilator produced in the vascular endothelium. Nebivolol enhances nitric oxide bioavailablility. Studies have also demonstrated nebivolol's ability to function as an antioxidant and decrease markers of oxidative stress. These effects are believed to ultimately produce a modulation of the endothelial dysfunction typically seen in hypertension.",
keywords = "β-blockers, Hypertension, Nebivolol, Nitric oxide",
author = "David Wojciechowski and Vasilios Papademetriou",
year = "2008",
month = "4",
day = "1",
doi = "10.1586/14779072.6.4.471",
language = "English (US)",
volume = "6",
pages = "471--479",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - β-blockers in the management of hypertension

T2 - Focus on nebivolol

AU - Wojciechowski, David

AU - Papademetriou, Vasilios

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Hypertension is a major cardiovascular risk factor but most patients remain asymptomatic for many years. Successful therapy not only needs to be effective, it also needs to be well tolerated. β-blockers are well established as effective antihypertensive agents. However, one major drawback to the currently available β-blockers, particularly the noncardioselective β-blockers, is their side-effect profile, including sexual dysfunction, fatigue, depression and metabolic abnormalities such as impaired glucose tolerance and lipid abnormalities. Nebivolol (Bystolic®), a novel, highly cardioselective, th ird-gene ration β-blocker that recently received approval by the US FDA for the treatment of hypertension in the USA, is effective in treating blood pressure and has a favorable side-effect profile. Studies conducted in Europe, where nebivolol has been available for some time for the treatment of hypertension, have shown that nebivolol achieves blood pressure reductions comparable to other β-blockers but with fewer side effects. Additionally, nebivolol has demonstrated similar efficacy in blood pressure reduction when compared with calcium channel blockers and inhibitors of the renin-angiotensin system. When combined with hydrochlorothiazicle there was an additive antihypertensive effect. Lastly, nebivolol exhibits a vasoclilatory property that is related to its effect on nitric oxide, an intrinsic vasodilator produced in the vascular endothelium. Nebivolol enhances nitric oxide bioavailablility. Studies have also demonstrated nebivolol's ability to function as an antioxidant and decrease markers of oxidative stress. These effects are believed to ultimately produce a modulation of the endothelial dysfunction typically seen in hypertension.

AB - Hypertension is a major cardiovascular risk factor but most patients remain asymptomatic for many years. Successful therapy not only needs to be effective, it also needs to be well tolerated. β-blockers are well established as effective antihypertensive agents. However, one major drawback to the currently available β-blockers, particularly the noncardioselective β-blockers, is their side-effect profile, including sexual dysfunction, fatigue, depression and metabolic abnormalities such as impaired glucose tolerance and lipid abnormalities. Nebivolol (Bystolic®), a novel, highly cardioselective, th ird-gene ration β-blocker that recently received approval by the US FDA for the treatment of hypertension in the USA, is effective in treating blood pressure and has a favorable side-effect profile. Studies conducted in Europe, where nebivolol has been available for some time for the treatment of hypertension, have shown that nebivolol achieves blood pressure reductions comparable to other β-blockers but with fewer side effects. Additionally, nebivolol has demonstrated similar efficacy in blood pressure reduction when compared with calcium channel blockers and inhibitors of the renin-angiotensin system. When combined with hydrochlorothiazicle there was an additive antihypertensive effect. Lastly, nebivolol exhibits a vasoclilatory property that is related to its effect on nitric oxide, an intrinsic vasodilator produced in the vascular endothelium. Nebivolol enhances nitric oxide bioavailablility. Studies have also demonstrated nebivolol's ability to function as an antioxidant and decrease markers of oxidative stress. These effects are believed to ultimately produce a modulation of the endothelial dysfunction typically seen in hypertension.

KW - β-blockers

KW - Hypertension

KW - Nebivolol

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=43049179911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049179911&partnerID=8YFLogxK

U2 - 10.1586/14779072.6.4.471

DO - 10.1586/14779072.6.4.471

M3 - Article

C2 - 18402537

AN - SCOPUS:43049179911

VL - 6

SP - 471

EP - 479

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 4

ER -